Moderna’s (NASDAQ:MRNA) Q4 Earnings Results: Revenue In Line With Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other hand, the company’s full-year revenue guidance of $2 billion at the midpoint came in 9.
Moderna Inc (MRNA) Q4 2024 Earnings Call Highlights: Navigating Challenges and Strategic Shifts
Despite a significant revenue decline, Moderna Inc (MRNA) focuses on strategic program prioritization and cost management to drive future growth.
Moderna Q4 2024 Earnings Preview: Decline in revenue expected
Moderna (NASDAQ:MRNA) is scheduled to announce Q4 earnings results on Friday, February 14th, before market open. Analysts expect a loss of $2.73 on revenue of $941.14M (-66.5% Y/Y). According to BofA Securities,
Moderna Q4 Earnings Preview: COVID-19 Vaccine Sales, Bird Flu Vaccine Candidates On Watch
Moderna, Inc. (NASDAQ:MRNA) is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in the report. What To Watch: Investors will be looking for updates on Moderna’s portfolio of mRNA-based vaccines and treatments across infectious diseases,
Moderna: Q4 Earnings Snapshot
Moderna Inc. (MRNA) on
Moderna (MRNA) Q4 2024 Earnings Call Transcript
Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator instructions] Please be advised,
Earnings call transcript: Moderna Q4 2024 sees revenue drop, market reacts
Moderna Inc . (BMV:MRNA) reported its fourth-quarter earnings for 2024, revealing a significant decline in revenue and a net loss. The company's earnings per share (EPS) were lower than expected, and the market responded with a notable drop in premarket trading.
Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline
Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $2.69. In the year-ago period, the company had reported earnings of 55 cents per share.
Moderna stock down pre-market on mixed 2024 earnings
Moderna reported mixed fourth quarter earnings, and full year 2024 earnings compared to Wall Street expectations Friday. Moderna's stock was down 4.5% in pre-market trading on the
Moderna swings to Q4 loss after nearly 66% drop in revenue
Moderna (NASDAQ:MRNA) shares fell ~5% in the premarket on Friday after the COVID-19 vaccine maker, with its Q4 2024 results, topped the consensus for revenue but missed Street forecasts for earnings following a ~66% YoY contraction in its topline.
Moderna Stock Falls on Earnings Report. The Results Reaffirm a Grim Picture for Vaccine Maker.
Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...
Moderna's Q4 Loss Wider Than Expected
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Moderna questioned on Trump, RFK Jr. impact on vaccine work
Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...
Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Wilmington Savings Fund Society FSB
Wilmington Savings Fund Society FSB grew its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 295.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 786 shares of the ...
Nasdaq12d
Moderna Options Trading: A Deep Dive into Market Sentiment
Looking at options history for Moderna (NASDAQ:MRNA) we detected 26 trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish ...
Moderna, Natwest, Fannie Mae set to report earnings Friday
Earnings season continues, and we're here to spotlight the companies expected to report their financial results on the next ...
Moderna Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $2.68 per share, versus earnings of 55 cents per share in the year-ago period. Moderna projects quarterly ...